Paolo Bossi: Immunotherapy plus cetuximab in advanced/metastatic cutaneous squamous cell carcinoma
Paolo Bossi, Head of the Head and Neck Medical Oncology Unit and Associate Professor of Medical Oncology at Humanitas University and Humanitas Cancer Center, shared a post on LinkedIn about a paper he co-authored with colleagues published in the European Journal of Cancer:
Authors: Paolo Bossi, Andrea Alberti, Cristiana Bergamini, Carlo Resteghini, Laura Deborah Locati, Luigi Lorini, Alberto Grammatica, Roberto Patuzzo, Andrea Maurichi, Lisa Francesca Licitra et al.
“I Tackle: second line with cetuximab and pembrolizumab in cutaneous squamous cell carcinoma.
Highlights:
- First study on PD-1 blockade + EGFR inhibition in recurrent/metastatic cSCC.
- Cetuximab overcame pembrolizumab resistance, reaching a 63 % cumulative ORR.
- Cetuximab reversed primary/acquired resistance in 43 % of cSCC cases, with safety.”
Luigi Lorini, Medical Oncologist at Humanitas Research Hospital, shared this post, adding:
“What about an EGFR inhibitor to reverse ICIs resistance in cutaneous squamous cell carcinoma?
Reach out our latest publication on this topic!”
More posts featuring Paolo Bossi and Luigi Lorini.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023